Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12300507 | 1.00 | PNP (0.63) | PNPHPRT1 | |
| SCHEMBL16199362 | 1.00 | PNP (0.63) | PNPHPRT1 | |
| SCHEMBL1738240 | 1.00 | PNP (0.63) | PNPHPRT1 | |
| SCHEMBL3302990 | 0.87 | PNP (0.81) | PNPHPRT1 | |
| SCHEMBL3302997 | 0.87 | PNP (0.81) | PNPHPRT1 | |
| SCHEMBL12300463 | 0.81 | PNP (0.52) | PNPHPRT1 | |
| SCHEMBL18512839 | 0.77 | LGALS8 (0.38) | PNP | |
| SCHEMBL12642169 | 0.77 | LGALS8 (0.38) | PNP | |
| SCHEMBL62167 | 0.77 | LGALS8 (0.38) | PNP | |
| SCHEMBL18513015 | 0.77 | LGALS8 (0.38) | PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170183373-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYERMASE | MERCK SHARP & DOHME CORP. (US) | 2017-06-29 | — | — | US | disclosed |
| US-20040014957-A1 | Oligonucleotides having modified nucleoside units | ISIS PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014957-A1 | Oligonucleotides having modified nucleoside units | RNASE1, RNASEH1, RNASEL | PNP 43/4885HPRT1 360/4885 |
| US-20170183373-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYERMASE | POLRMT, DUT, RNASE1 | PNP 13/4885HPRT1 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.